UK markets closed

Hutchison China MediTech Limited (HCM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
32.170.00 (0.00%)
At close: 4:00PM EDT
32.17 0.00 (0.00%)
After hours: 04:41PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close32.17
Bid30.02 x 1100
Ask37.45 x 1000
Day's range32.01 - 32.44
52-week range23.67 - 43.94
Avg. volume198,428
Market cap5.609B
Beta (5Y monthly)0.67
PE ratio (TTM)N/A
EPS (TTM)-1.24
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est46.57
  • Zacks

    Hutchison China MediTech (HCM) Loses 19.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

    Hutchison China MediTech (HCM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

  • Globe Newswire

    HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual Meeting

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 28, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) announces that new and updated clinical data from several ongoing combination studies of surufatinib (SULANDA® in China) or fruquintinib (ELUNATE® in China) with PD-1 inhibitors were presented at the 24th Chinese Society of Clinical Oncology (CSCO) Annual Meeting which has been taking place on September 25-29, 2021. SURUFATINIB Title:A phase I

  • Globe Newswire

    HUTCHMED Announces Closing of Divestment of Non-Core OTC Joint Venture

    HONG KONG and FLORHAM PARK, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that, further to its announcement in March 2021 and following receipt of regulatory approval, it has completed the sale of its entire indirect interest in Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”), a non-core and non-consolidated over-the-counter (“OTC”) drug joint venture business, to GL Mountrose Investment